Effect of Sacubitril-Valsartan versus angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blocker (ARB) on left ventricular ejection fraction in patient with heart failure

Effect of Sacubitril-Valsartan versus angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blocker (ARB) on left ventricular ejection fraction in patient with heart failure: a double-blind randomized clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120215009014N503

Enrollment

225

Registered

2024-03-13

Start date

2024-04-20

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure. Heart failure

Interventions

Intervention 1: Intervention group 1: Sacubitril-valsartan tablets 24/26 mg every 12 hours for 6 months. Intervention 2: Intervention group 2: Angiotensin converting enzyme inhibitor (ACEI) 12/5 mg ev

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Age 18 to 80 years Heart failure

Exclusion criteria

Exclusion criteria: Severe coronary disease Valvular heart disease Pulmonary thromboembolism Congenital heart disease

Design outcomes

Primary

Measure	Time frame
Average blood pressure. Timepoint: Every 2 weeks for 6 months after the intervention. Method of measurement: Using a sphygmomanometer.;Mean serum creatinine. Timepoint: Every 2 weeks for 6 months after the intervention. Method of measurement: By taking blood samples.;The average quality of life score. Timepoint: Every 2 weeks for 6 months after the intervention. Method of measurement: Using the New York Heart Association (NYHA) questionnaire.;Left heart ejection fraction. Timepoint: Every 2 weeks for 6 months after intervention. Method of measurement: With echocardiography.;The frequency and duration of hospitalization. Timepoint: Within 6 months after the intervention. Method of measurement: By examining the medical record.;The occurrence of death. Timepoint: Within 6 months after the intervention. Method of measurement: By examining the medical record.	—

Measure

Time frame

Average blood pressure. Timepoint: Every 2 weeks for 6 months after the intervention. Method of measurement: Using a sphygmomanometer.;Mean serum creatinine. Timepoint: Every 2 weeks for 6 months after the intervention. Method of measurement: By taking blood samples.;The average quality of life score. Timepoint: Every 2 weeks for 6 months after the intervention. Method of measurement: Using the New York Heart Association (NYHA) questionnaire.;Left heart ejection fraction. Timepoint: Every 2 weeks for 6 months after intervention. Method of measurement: With echocardiography.;The frequency and duration of hospitalization. Timepoint: Within 6 months after the intervention. Method of measurement: By examining the medical record.;The occurrence of death. Timepoint: Within 6 months after the intervention. Method of measurement: By examining the medical record.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Farnoosh Masmou

Hamedan University of Medical Sciences

farnooshmasmou@yahoo.com+98 81 3838 0572

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026